Merck’s (NYSE: MRK) Q4 and full-year 2025 sales performance reflects strength across oncology and animal health, as well as increasing contributions from new launches. Our company announced Q4 worldwide sales of $16.4 billion. Full-year 2025 worldwide sales were $65.0 billion.
“In 2025, we continued to advance leading-edge science to deliver transformative medicines and vaccines that are improving health outcomes for patients around the world,” said Rob Davis, chairman and CEO. “Our business benefited from demand for our innovative portfolio, including for KEYTRUDA, increasing contributions from new launches in cardiometabolic and respiratory as well as vaccines, and strong performance of Animal Health. The transformation of our portfolio, bolstered by the acquisitions of Verona Pharma and Cidara Therapeutics, is well underway, and momentum is building as we continue to execute on our strategy. Our progress positions us to continue delivering on our purpose for patients and creating durable value for shareholders.”
Merck anticipates full-year 2026 worldwide sales to be between $65.5 billion and $67.0 billion.
